Here at TheraPYX we have developed EXStaM (patent pending), a unique process that is able to produce commercial grade sustained-release microparticulate protein therapeutics suitable for oral and mucosal delivery.
What Sets Our Technology Apart
EXStaM represents a breakthrough in encapsulation of biological macromolecules. Not only does this process allow the macromolecule to maintain full biological activity, but it consistently produces a shelf-stable drug product that sustains physiological levels of the active protein in the disease microenvironment. This is a unique accomplishment in our industry and provides significant advantages over competing biologics. We continue to use the EXStaM platform to expand our protein-based product pipeline in generating human-like therapeutics with selective and predictable activity.
Innovating Cost-Effective, Shelf-Stable Drug Products
Patents and other proprietary rights are critical to our business at TheraPYX. We aggressively file new patent applications to protect our technology, inventions, and improvements. We have exclusive worldwide licenses from Brown University for a proprietary protein micronization and encapsulation process. Based on this method we have developed a unique second-generation platform technology, EXStaM (patent pending) that allows commercial scale microencapsulation of therapeutic proteins. Several of our methods and selection patents that protect specific products in specific indications have either been licensed, awarded, or are currently pending – including the applications covering our general scale-up methods that allow the consistent production of large batches of commercial-grade drug product.